Parnell Pharmaceuticals Holdings Ltd. reported unaudited consolidated earnings results for the nine months ended September 30, 2018. For the nine months, the company reported revenue of AUD 19,982,608 compared to AUD 14,363,194 a year ago. Profit for the period was AUD 1,272,535 compared to loss for the period of AUD 8,422,710 a year ago.

The ongoing 2018 business performance achieved to 30 September allows the Board to reaffirm full-year 2018 guidance of 35% to 40% revenue growth to AUD 26 million to AUD 27 million, over initial revenue 2018 guidance of AUD 25 million to AUD 26 million.